Regeneron Pharmaceuticals, Inc.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| REGN.MX | 068270.KS | BIOCON.NS | ROIV | 1801.HK | RPRX | |
|---|---|---|---|---|---|---|
| Market cap | 1.37T | 45.19T | 556.84B | 24.86B | 155.29B | 34.85B |
| P/E (TTM) | 18.3 | — | 100.6 | — | 117.2 | 32.1 |
| Forward P/E | — | — | 31.0 | -20.0 | 35.2 | 10.4 |
| Price/book | 2.3 | — | 1.6 | 5.9 | 6.4 | 3.9 |
| Dividend yield | 0.48% | 0.37% | 0.14% | — | — | 1.54% |
| 1-year change | +23.69% | +15.02% | −4.14% | +89.01% | +3.43% | +66.42% |
| Today | 0.00% | +2.16% | −2.63% | +2.65% | +1.48% | −1.07% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All REGN.MX news ›Regeneron Pharmaceuticals, Inc. Announces Libtayo® Recommended For EU Approval By The CHMP For Updated Dosing Regimen Across All Approved Cancer Types
Regeneron Pharmaceuticals, Inc. announced that the European Medicines Agency?s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of an... announced that the European Medicines Agency?s…
What to Expect From Regeneron Pharmaceuticals' Next Quarterly Earnings Report
Barchart.com
2,281 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by First Citizens Bank & Trust Co.
Posted by Defense World Staff on Oct 16th, 2026 First Citizens Bank & Trust Co. bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the third quarter, according to the company in its most…
Regeneron Pharmaceuticals, Inc. $REGN Stock Sold by Curated Wealth Partners LLC
MarketBeat Regeneron Pharmaceuticals, Inc. $REGN Stock Sold by Curated Wealth Partners LLC - Curated Wealth Partners cut its Regeneron stake by 96.3% in the third quarter, selling 35,373 shares and retaining 1,365 shares worth…
UBS Upgrades Regeneron Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $978 From $660
Regeneron Pharmaceuticals has an average rating of overweight and mean price target of $869.08, according to analysts polled by FactSet. Price: 795.02, Change: +16.66, Percent Change: +2.14 ... Published on 10/15/2026 at 10:38 am EDT…
Geron Lawsuit Ruling: Court Allows Investor Claims Over Rytelo Sales Statements to Move Forward
A federal judge in California has denied the defendant’s motion to dismiss an investor lawsuit alleging that the company and certain executives made false or misleading statements about Rytelo’s commercial progress. The ruling means the…
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share
In the second quarter, Regeneron's revenue grew by a healthy 17% year over year to $4.3 billion. Global sales of Dupixent came in at $6 billion, up 38% year over year. Regeneron's revenue generated from its collaboration with Sanofi grew…
Why Regeneron (REGN) Stock Is Down Today
Shares of biotech company Regeneron (NASDAQ: REGN) fell 4.8% in the afternoon session after a court ruling in Australia dealt a blow to the company's efforts to block a competing version of its blockbuster eye drug, EYLEA. The stock market…
UBS Upgrades Regeneron Pharmaceuticals (REGN) on Next-Gen Dupixent Potential
On October 14, 2026, UBS upgraded Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to a Buy rating, citing undervaluation in the market related to the company’s promising pipeline of successors to its blockbuster drug Dupixent. The firm set a…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com37
-
tradingview.com15
-
gurufocus.com14
-
theglobeandmail.com13
-
seekingalpha.com12
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.